Latest Information Update: 05 Jul 2006
At a glance
- Originator Roche
- Class Obesity therapies
- Mechanism of Action G protein-coupled receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 05 Jul 2006 No development reported - Preclinical for Obesity in Switzerland (unspecified route)
- 19 Apr 2004 Preclinical trials in Obesity in Switzerland (unspecified route)